Canine AGP antibody and antigen (recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-CAN-AGP-Ag01	Recombinant Canine AGP protein	3090
GMP-CAN-AGP-Ab01	Anti-Canine AGP mouse monoclonal antibody (mAb)	1953
GMP-CAN-AGP-Ab02	Anti-Canine AGP mouse monoclonal antibody (mAb)	1953
GMP-CAN-AGP-Ab03	Anti-Canine AGP human monoclonal antibody (mAb)	1953
GMP-CAN-AGP-Ab04	Anti-Canine AGP human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-CAN-AGP-Ag01
Product Name	Recombinant Canine AGP protein
Target/Biomarker	Canine Alpha-1-acid glycoprotein (AGP)
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Canine Alpha-1-acid glycoprotein antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in AGP level test of animal Dog/Canine with Systemic Inflammation.
Tag	His
Products description	Recombinant Canine AGP protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-CAN-AGP-Ab01, GMP-CAN-AGP-Ab02
Product Name	Anti-Canine AGP mouse monoclonal antibody (mAb)
Target/Biomarker	Canine Alpha-1-acid glycoprotein (AGP)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Canine Alpha-1-acid glycoprotein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-AGP antibodies in AGP level test of animal Dog/Canine with Systemic Inflammation.
Tag	mFc
Products description	Anti-Canine AGP mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-AGP antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-CAN-AGP-Ab03, GMP-CAN-AGP-Ab04
Product Name	Anti-Canine AGP human monoclonal antibody (mAb)
Target/Biomarker	Canine Alpha-1-acid glycoprotein (AGP)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Recombinant Canine Alpha-1-acid glycoprotein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-AGP antibodies in AGP level test of animal Dog/Canine with Systemic Inflammation.
Tag	hFc
Products description	Anti-Canine AGP human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-AGP antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Alpha-1 Acid Glycoprotein (AGP), in the context of canine health, serves as a pivotal biomarker for identifying and monitoring inflammation, infection, and disease states in dogs. This acute phase protein, also known in veterinary circles as Dog/Canine AGP, rises in response to systemic stressors such as infection, inflammation, and trauma, offering veterinarians a sensitive and specific tool for assessing the health status of their canine patients. AGP's role in canine medicine is multifaceted. Primarily, it acts as an early warning system, alerting veterinarians to underlying health issues before clinical symptoms become evident. This is particularly valuable for diseases that progress silently or are in their nascent stages, such as certain cancers, autoimmune diseases, or chronic infections. By enabling early detection, AGP measurements can facilitate prompt intervention, potentially improving the outcome for the affected dog. Beyond its utility in detection, Dog/Canine AGP is instrumental in monitoring disease progression and treatment efficacy. For chronic conditions or diseases requiring long-term management, AGP levels can reflect changes in the disease state, helping veterinarians tailor treatment plans to the individual needs of their patients. A decrease in AGP levels often signifies a positive response to treatment, while an increase may indicate a worsening condition or the emergence of complications. Moreover, AGP serves as a prognostic indicator in canine health. Elevated AGP levels at diagnosis or during treatment can be associated with more severe disease presentations and may have prognostic implications. This information aids veterinarians in making informed decisions about treatment options and managing pet owner expectations regarding their dog's health outcomes. The assessment of AGP levels in dogs is achieved through specific diagnostic tests that measure this protein's concentration in the blood. The development and refinement of these tests underscore the growing recognition of the importance of species-specific biomarkers in veterinary medicine. As research continues to evolve, the potential for AGP and other biomarkers to refine our understanding of canine diseases and improve clinical outcomes for dogs is significant. In summary, Dog/Canine AGP is an essential biomarker for detecting, monitoring, and prognosticating health issues in dogs. Its ability to signal the presence of systemic inflammation and disease before the onset of overt clinical symptoms empowers veterinarians to act proactively in managing canine health. Furthermore, its role in evaluating treatment effectiveness and disease progression enhances the precision of canine medical care. As veterinary science advances, the role of AGP and similar biomarkers in improving the diagnosis, treatment, and management of canine diseases is likely to expand, offering new avenues for enhancing the health and well-being of dogs.

About GDU